Cantor Fitzgerald Expects Stronger Earnings for MannKind

MannKind Co. (NASDAQ:MNKD - Free Report) - Equities researchers at Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for MannKind in a research report issued to clients and investors on Monday, May 12th. Cantor Fitzgerald analyst O. Brayer now anticipates that the biopharmaceutical company will post earnings of $0.23 per share for the year, up from their prior forecast of $0.18. The consensus estimate for MannKind's current full-year earnings is $0.10 per share.

MannKind (NASDAQ:MNKD - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.03 by $0.01. MannKind had a negative return on equity of 17.74% and a net margin of 8.07%. The firm had revenue of $78.35 million for the quarter, compared to analyst estimates of $75.86 million. During the same period last year, the company earned $0.05 EPS. The firm's quarterly revenue was up 18.1% on a year-over-year basis.

MNKD has been the subject of several other reports. Wedbush reissued an "outperform" rating and set a $11.00 price objective on shares of MannKind in a research note on Thursday, February 27th. Mizuho began coverage on MannKind in a research note on Thursday, April 10th. They set an "outperform" rating and a $12.00 price target for the company. Finally, StockNews.com raised MannKind from a "hold" rating to a "buy" rating in a research note on Wednesday, March 19th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $10.00.

MannKind Stock Performance

MNKD opened at $4.72 on Wednesday. MannKind has a 1 year low of $4.34 and a 1 year high of $7.63. The company's 50 day simple moving average is $4.88 and its 200 day simple moving average is $5.80. The stock has a market capitalization of $1.43 billion, a PE ratio of 67.43 and a beta of 1.14.

Institutional Investors Weigh In On MannKind

Hedge funds and other institutional investors have recently bought and sold shares of the business. Raymond James Financial Inc. boosted its stake in shares of MannKind by 1.3% during the 1st quarter. Raymond James Financial Inc. now owns 662,821 shares of the biopharmaceutical company's stock valued at $3,334,000 after buying an additional 8,197 shares during the last quarter. Fox Run Management L.L.C. raised its holdings in MannKind by 184.5% in the first quarter. Fox Run Management L.L.C. now owns 74,024 shares of the biopharmaceutical company's stock valued at $372,000 after acquiring an additional 48,009 shares in the last quarter. E Fund Management Co. Ltd. boosted its stake in MannKind by 11.9% during the 1st quarter. E Fund Management Co. Ltd. now owns 24,667 shares of the biopharmaceutical company's stock valued at $124,000 after acquiring an additional 2,628 shares during the last quarter. Nuveen LLC bought a new position in MannKind during the 1st quarter valued at $17,011,000. Finally, Virtu Financial LLC acquired a new position in MannKind during the 1st quarter worth $70,000. 49.55% of the stock is currently owned by hedge funds and other institutional investors.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.